Terry,
No secondary that I'm aware of for DANB. There were just some rumors in the past thay there might be due to the cash-poor position, expenses of opening up new stores, and the
questionable effects of being a spin off from Edison. The real key will probably be this week's earnings, though.
I agree about SBAM. Lot of articles, but not much factual info thus far. Possibly a lot of potential, but still more like gambling(like other stocks aren't?!).
I have lots to say about ATIS, as you might gather. I'd recommend if you're interested to read the ATIS thread on biotech. A couple of weeks ago I posted a big blurb after talking with the company,
as well as info about their products and where all seems to be on the time-frame. What I particularly like is that the potential for what they're working on is huge, and with the risk of biotech, it should be, and
not enough really are. There isn't a load of competition, and the whole tissue repair industry may actually be something separate from true biotech if it takes off like I think it will. They seem to be poised to be the
industry leader, and the IBD shows a steady increase in sponsorship over the last few months. If you're still interested after reading more, I'll be happy to discuss what I know, which may only further clarify how little
that truly is.
Regards,
Marshall |
